Pediatrix Medical Group (MD) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.72
- Estimate
- $0.65
- Surprise
- +10.8%
- Revenue (period 2026-09-30)
- $501.4M
- Score at report (before → after)
- 5.3 → 5.6/10
Revenue source: xbrl.
How the report landed
Pediatrix Medical Group (MD) beat the $0.65 estimate with adjusted EPS of $0.72 — a large 10.8% upside surprise. TrendMatrix's engine moved from Sell (5.3/10) to Hold at 5.6/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates MD Sell at 5.4/10.
3 of the last 4 quarters beat the estimate; this quarter's +10.8% surprise compares with a +6.6% four-quarter average. Next scheduled report: 2027-02-18.
What supports the rating
- Strong earnings beat streak (3/4)
- Attractive valuation
What argues against it
- Analyst target reached - limited upside remaining
- Negative momentum
- Target reached (-14.4% upside)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $30.57
- Stop
- $28.43
The stock trades at 17.0× trailing but 12.4× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-11-18 — shown for context, not personalized investment advice.
MD at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Care Facilities
- Market cap
- $2.43B
- P/E (fwd)
- 12.4
- P/E (ttm)
- 17.0
- 52-week range
- $17.23–$33.74
- Off 52-week high
- 9.4%
- RSI (14)
- 59
- Volume vs avg
- 0.45×
- Score today
- 5.4/10